Targeted Oncology Staff

In separate live virtual events, Sarah A. Holstein, MD, PhD, and Shashank Cingam, MD, discuss options for a patient with relapsed/refractory multiple myeloma and the use of chimeric antigen receptor (CAR) T-cell therapy.

In part 2, experts discuss optimizing the use of JAK inhibitors for patients with myelofibrosis.

During a live event, Jack Khouri, MD, discusses selinexor-based therapies for relapsed multiple myeloma, emphasizing AE management and weekly dosing.

During a Community Case Forum event, Antoinette R. Tan, MD, MHS, discussed the DESTINY-Breast04 and DESTINY-Breast06 trials in HER2-low and -ultralow breast cancer.

During a live event, Xiuning Le, MD, PhD, discussed clinical trials of supportive care for infusion reaction and skin rash with amivantamab in EGFR-mutated lung cancer.

During a live event, Pedro C. Barata, MD, MSc, discussed the case of a patient with advanced clear cell renal cell carcinoma who requires second-line therapy.

During a live event, Shuo Ma, MD, PhD, discussed the resistance mutation analysis of patients who had disease progression after receiving pirtobrutinib for BTK inhibitor–pretreated chronic lymphocytic leukemia.

During a live event, Karen Seiter, MD, discussed the role of the JAK/STAT pathway in myeloproliferative neoplasms and the use of ruxolitinib to treat myelofibrosis.

During a live event, Gregory Vidal, MD, PhD, discussed the adjuvant trials of abemaciclib and ribociclib and how their different dosing approaches and safety profiles can affect their usage in breast cancer.

During a live event, Shuo Ma, MD, PhD, discussed the outcomes of the BRUIN trial of pirtobrutinib in BTK inhibitor–pretreated chronic lymphocytic leukemia.

During a live event, Megan Kruse, MD, discussed sacituzumab govitecan's benefit, dosing, toxicity, and an ongoing earlier-line trial in metastatic breast cancer.

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the IsKia, MASTER, and CONCEPT clinical trials of frontline therapy in multiple myeloma.

During a live event, Ahmad Tarhini, MD, PhD, discussed the RELATIVITY-047 trial of nivolumab/relatlimab vs nivolumab alone in advanced melanoma.

During a live event, Krish Patel, MD, discussed barriers to using bispecific T-cell engagers and practical considerations of using loncastuximab in a patient with relapsed diffuse large B-cell lymphoma who had prior CAR T-cell therapy.

During a live event, Daniel M. Geynisman, MD, and participants discussed which efficacy end points they value and how they modify doses of combination renal cell carcinoma therapies.

During a live event, Krish Patel, MD, surveyed participants on using bispecific T-cell engagers vs loncastuximab in a patient with relapsed diffuse large B-cell lymphoma who had prior CAR T-cell therapy.

Check out the latest oncology news from this week, including highlights from the 2025 American Association for Cancer Research and American Urological Association Annual Meetings.

Douglas Sborov, MD, discusses adverse events in the MajesTEC-1 study of teclistamab in multiple myeloma.

During a live event, Ahmad Tarhini, MD, PhD, discussed key melanoma trials with varying survival and toxicity profiles.

During a live event, Naresh Bumma, MD, discussed talquetamab’s efficacy in relapsed/refractory multiple myeloma, including high-risk patients.

During a live event, Mark J. Fesler, MD, and participants discussed selection and timing of initiation of JAK inhibitor therapy for myelofibrosis.

In part 1, experts explores how assessing individual risk factors is crucial in selecting the appropriate JAK inhibitor for patients with myelofibrosis.

During a live event, Jack Khouri, MD, discussed options for patients with multiple myeloma after relapse and choices to consider before CAR T-cell therapy.

During a live event, Guru P. Sonpavde, MD discussed improvements to survival with cabozantinib plus nivolumab in metastatic renal cell carcinoma.

During a live event, Nathan M. Denlinger, DO, MS, discussed the TRANSFORM trial of lisocabtagene maraleucel in B-cell lymphoma and its crossover design.

During a live event, Mark J. Fesler, MD, and participants discuss next steps for a 68-year-old patient with intermediate-risk myelofibrosis.

During a Community Case Forum event, Stacey Stein, MD, discussed data guiding the use of current regimens for the treatment of unresectable hepatocellular carcinoma.

During a live event, Xiuning Le, MD, PhD, discussed updated intracranial efficacy, overall survival, and safety of amivantamab plus lazertinib in patients with EGFR-mutated non–small cell lung cancer.

During a live event, Richard F. Riedel, MD, discussed key efficacy and safety outcomes from the phase 3 DeFi trial in patients with progressing desmoid tumors.

During a live event, Shannon N. Westin, MD, MPH, and participants discussed their experience treating patients with progressive cervical cancer and the toxicity profile of tisotumab vedotin.